Brain Chemical Differences in Parkinson's Disease With and Without the LRRK2 Gene Mutation
Compares brain scans and tests in people with Parkinson's disease, with and without LRRK2.
Plain-language title generated from the registry record
Registry title: Striatal and Extra-Striatal Cholinergic Terminal Density in LRRK2-PD Mutation
Key facts
- Where
- Ann Arbor, United StatesSee the site
Where in United States
- University of MichiganAnn Arbor, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Michigan
- Trial code
- NCT07642908
- Record updated
- 6 November 2026
- Original description
This study explores how a specific genetic mutation of leucine-rich repeat kinase 2 (LRRK2) affects individuals with Parkinson's disease (PD), comparing those with the mutation to others with Parkinson's disease and without the mutation (iPD). Participants will complete positron emission tomography (PET) and magnetic resonance imaging (MRI) brain imaging, cognitive tests, motor tests, sensory tests, and questionnaires. The aims of this study are to compare brain chemicals in LRRK2 PD patients with iPD patients and to correlate brain chemicals with motor and cognitive tests in LRRK2 PD and iPD patients.Read full original descriptionShow less
Striatal and Extra-Striatal Cholinergic Terminal Density in LRRK2-PD Mutation
This study explores how a specific genetic mutation of leucine-rich repeat kinase 2 (LRRK2) affects individuals with Parkinson's disease (PD), comparing those with the mutation to others with Parkinson's disease and without the mutation (iPD). Participants will complete positron emission tomography (PET) and magnetic resonance imaging (MRI) brain imaging, cognitive tests, motor tests, sensory tests, and questionnaires. The aims of this study are to compare brain chemicals in LRRK2 PD patients with iPD patients and to correlate brain chemicals with motor and cognitive tests in LRRK2 PD and iPD patients.
Inclusion: Male or Female, age 45 years and over; Diagnosis of PD based on the United Kingdom Parkinson's Disease Society Brain Bank Diagnostic Research Criteria (Hughes et al., 1992); Presence of LRRK2 mutation as confirmed by referral from UM Movement Disorders clinic, medical record review, or participation in the PDGENEration study.
Exclusion: Contra-indications to MR imaging including but not limited to pacemakers, aneurysm clips, intraocular metal, cochlear implant, or severe claustrophobia; Regular use of typical anti-cholinergic drugs or cholinesterase inhibitors; Evidence of large vessel stroke or mass lesion on MRI; History of deep brain stimulation surgery; Cognitive impairment that results in the inability to give consent, as demonstrated by the Decision Making Capacity Tool; Any other condition or criterion that would preclude safe and meaningful participation in the study; Evidence of atypical parkinsonism; Pregnant or nursing; Suicidal ideation, as indicated by a response of 2 or 3 on question 9 of the Beck Depression Inventory.